Table 3.
Quality assessment of the included studies.
| Author, Year | Title | Demographics | Current Health Status | Medical History | Physical Examination | Patient Disposition | Drug Identification | Dosage | Administration Drug- Reaction Interface | Concomitant Therapies | Adverse Events | Discussion | Overall Rating |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aksu, 2021 | ● | ● | ● | ● | ● | ● | ○ | ● | ● | ● | ○ | ● | 10 |
| Alpalhão, 2021 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | 12 |
| Arora, 2021 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | 12 |
| Bostan, 2021 | ● | ● | ● | ● | ● | ○ | ○ | ● | ○ | ● | ○ | ● | 8 |
| Català, 2021 | ● | ● | ○ | ● | ○ | ● | ● | ● | ○ | ○ | ● | ● | 8 |
| Chiu, 2021 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ○ | ○ | ● | 10 |
| Eid, 2021 |
● | ● | ● | ● | ● | ○ | ○ | ● | ○ | ● | ● | ● | 9 |
| Furer, 2021 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | 12 |
| Lee, 2021 |
● | ● | ● | ● | ● | ○ | ● | ● | ● | ○ | ● | ● | 10 |
| Psichogiou, 2021 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | 12 |
| Rodriguez-Jimenez, 2021 | ● | ● | ● | ● | ● | ○ | ● | ● | ● | ● | ○ | ● | 10 |
| Tessas, 2021 | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | 12 |
Key: ○ = 0, ● = 1.